DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)

VANCOUVER, British Columbia and MENLO PARK, Calif., May 11, 2017 /PRNewswire/ —¬†DelMar Pharmaceuticals (DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on developing new cancer therapies, today announced the formalization of an agreement with PRA Health Sciences (PRAH), a leading contract research organization (CRO) to conduct the Company’s Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).